| A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy (NCT07225556) | Eli Lilly and Company | 2025-11-18 |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (NCT07192432) | Vironexis Biotherapeutics Inc. | 2025-11-18 |
| A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia (NCT07233018) | MEI HENG | 2025-11-18 |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity (NCT07243171) | Hangzhou Sciwind Biosciences Co., Ltd. | 2025-11-18 |
| A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (NCT07186842) | BioNTech SE | 2025-11-18 |
| A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People (NCT07238816) | Novo Nordisk A/S | 2025-11-18 |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia (NCT07175493) | Keymed Biosciences Co.Ltd | 2025-11-18 |
| A Pharmacokinetic Study of YN001 in Healthy Participants (NCT07190885) | Beijing Inno Medicine Co., Ltd. | 2025-11-18 |
| Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers (NCT06977126) | University Health Network, Toronto | 2025-11-18 |
| A Phase 1 Study of HDM2017 in Advanced Solid Tumors (NCT07274085) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-11-18 |
| Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma (NCT07182565) | West China Hospital | 2025-11-18 |
| Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease (NCT07221344) | Arrowhead Pharmaceuticals | 2025-11-18 |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia (NCT07295951) | Janssen Research & Development, LLC | 2025-11-18 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (NCT07218003) | Rondo Therapeutics | 2025-11-17 |
| A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia (NCT07231120) | Jiangsu Nutai Biologics Co., Ltd | 2025-11-17 |
| Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults (NCT07295028) | Sanofi | 2025-11-17 |
| Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism (NCT07530705) | Peking Union Medical College Hospital | 2025-11-17 |
| Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries (NCT07240402) | Kafrelsheikh University | 2025-11-17 |
| to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (NCT07265466) | Onconic Therapeutics Inc. | 2025-11-17 |
| Study Evaluating Safety of BT01001 Ophthalmic Solution (NCT07313722) | Beyang Therapeutics Co., Ltd. | 2025-11-17 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial (NCT06811116) | National Cancer Institute (NCI) | 2025-11-17 |
| A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (NCT06887803) | iOnctura | 2025-11-17 |
| Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (NCT07128888) | Gan & Lee Pharmaceuticals. | 2025-11-17 |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors (NCT07095868) | Everest Medicines (Beijing) Co., Ltd. | 2025-11-17 |
| Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants (NCT07350577) | AltruBio Inc. | 2025-11-17 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer (NCT07198724) | Kristina A. Fanucci | 2025-11-17 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection (NCT07241923) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-11-15 |
| Improving Walking After Spinal Cord Injury (NCT07223710) | Shirley Ryan AbilityLab | 2025-11-15 |
| Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma (NCT07237425) | Glonova Pharma Co., Ltd | 2025-11-14 |
| A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (NCT07232407) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-11-14 |
| A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (NCT07231978) | Pfizer | 2025-11-14 |
| PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers (NCT07256600) | Daewoong Pharmaceutical Co. LTD. | 2025-11-14 |
| A Clinical Study of PA5 in Patients With Advanced Solid Tumors (NCT07702162) | Chongqing Peg-Bio Biopharm Co., Ltd. | 2025-11-14 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation (NCT07162038) | National Cancer Institute (NCI) | 2025-11-14 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (NCT07085104) | Allogene Therapeutics | 2025-11-13 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases (NCT07236801) | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2025-11-13 |
| A Study of DEG6498 in Participants With Solid Tumors (NCT07244835) | Degron Therapeutics Co. | 2025-11-13 |
| Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants (NCT07218744) | Incyte Corporation | 2025-11-13 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (NCT07241936) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-11-13 |
| Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (NCT07421037) | Ab&B Bio-tech Co., Ltd.JS | 2025-11-13 |
| Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (NCT07421050) | Ab&B Bio-tech Co., Ltd.JS | 2025-11-13 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years (NCT06732583) | CanSino Biologics Inc. | 2025-11-13 |
| A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT07229313) | Kivu Bioscience Inc. | 2025-11-13 |
| A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC (NCT07255664) | CuraCell TX AB | 2025-11-13 |
| HS-20117-2 Injection in Patients With Advanced Solid Tumors (NCT07775703) | Hansoh BioMedical R&D Company | 2025-11-13 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas (NCT07217171) | EvolveImmune United, Inc | 2025-11-13 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants (NCT07225296) | Genosco Inc. | 2025-11-12 |
| A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants (NCT07226817) | Bristol-Myers Squibb | 2025-11-12 |
| First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors (NCT07265622) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-11-12 |
| Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia (NCT07206758) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-11-12 |
| Maintenance Zanzalintinib With Etoposide After HDCT in GCT (NCT06937866) | Indiana University | 2025-11-12 |
| Actinium Therapy for Late-stage Aggressive Sarcomas (NCT07156565) | Ratio Therapeutics, Inc. | 2025-11-12 |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (NCT07109219) | AstraZeneca | 2025-11-12 |
| RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma (NCT07150806) | Joshua Palmer | 2025-11-12 |
| AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study (NCT07285395) | The Affiliated Hospital of Xuzhou Medical University | 2025-11-12 |
| A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin (NCT07308041) | Cinclus Pharma Holding AB | 2025-11-11 |
| A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 (NCT07220954) | AstraZeneca | 2025-11-11 |
| Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors (NCT07081984) | Therorna | 2025-11-11 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment (NCT07282093) | Ascentage Pharma Group Inc. | 2025-11-11 |
| Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma (NCT07300683) | University College, London | 2025-11-11 |
| Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites (NCT07149090) | Asan Medical Center | 2025-11-11 |
| A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (NCT07232420) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-11-11 |
| Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers (NCT07246291) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2025-11-11 |
| Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis (NCT07329101) | Jiangsu vcare pharmaceutical technology co., LTD | 2025-11-11 |
| Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint (NCT06981741) | BIONCaRT GmbH | 2025-11-10 |
| Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers (NCT07396376) | Eluciderm Inc | 2025-11-10 |
| A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (NCT07181681) | BeOne Medicines | 2025-11-10 |
| A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years (NCT07216131) | AstraZeneca | 2025-11-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes (NCT07230418) | Chengdu Suncadia Medicine Co., Ltd. | 2025-11-10 |
| A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects (NCT07479576) | Qilu Pharmaceutical Co., Ltd. | 2025-11-10 |
| An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (NCT07495007) | Zi Diligence Biocenter | 2025-11-10 |
| GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms (NCT07306156) | Zhimin Zhai | 2025-11-10 |
| Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease (NCT07228364) | AstraZeneca | 2025-11-10 |
| Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults (NCT07213310) | Daewoong Pharmaceutical Co. LTD. | 2025-11-09 |
| Exploratory Study of Inhaled Afatinib Dimaleate PK Profile (NCT06897735) | Petrov, Andrey | 2025-11-09 |
| A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants (NCT07155980) | Acta Pharmaceuticals | 2025-11-09 |
| A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) (NCT07300085) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-11-08 |
| Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments (NCT07154511) | Prabesh Kanel | 2025-11-07 |
| Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (NCT07711223) | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 2025-11-07 |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors (NCT07265921) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-11-07 |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer (NCT07227168) | Sutro Biopharma, Inc. | 2025-11-07 |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) (NCT07225816) | Novo Nordisk A/S | 2025-11-07 |
| TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma (NCT07189195) | University of California, Davis | 2025-11-07 |
| Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects (NCT07239453) | Dong-A ST Co., Ltd. | 2025-11-07 |
| MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers (NCT06911008) | Mayo Clinic | 2025-11-07 |
| Early Phase Study of KESONOTIDE™in Participants With Solid Tumours (NCT06926075) | Filamon LTD | 2025-11-07 |
| A Study to Assess the Effect of Food on the Drug Levels of Admilparant (NCT07225647) | Bristol-Myers Squibb | 2025-11-07 |
| Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas (NCT07052383) | Tcelltech Inc. | 2025-11-06 |
| A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (NCT07178171) | Xijing Hospital | 2025-11-06 |
| A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants (NCT07219589) | Hanmi Pharmaceutical Company Limited | 2025-11-06 |
| Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases (NCT07361094) | Beijing Boren Hospital | 2025-11-06 |
| A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation (NCT06990711) | Washington University School of Medicine | 2025-11-06 |
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation (NCT07221760) | n-Lorem Foundation | 2025-11-06 |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (NCT07206225) | Pfizer | 2025-11-06 |
| A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray (NCT07259538) | VivaVision Biotech, Inc | 2025-11-06 |
| Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. (NCT07421011) | Valenta Pharm JSC | 2025-11-06 |
| Study of BB-025, Alone and After BB-031, in Healthy Volunteers (NCT07202663) | Basking Biosciences, Inc. | 2025-11-05 |
| An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma (NCT07399821) | Princess Maxima Center for Pediatric Oncology | 2025-11-05 |
| Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis (NCT06750588) | Nterica Bio inc | 2025-11-05 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (NCT07198633) | Qilu Pharmaceutical Co., Ltd. | 2025-11-05 |